Defense World
07 Dec 2025, 07:20 UTC · 40w ago
Verdict
Headline takes no side. We score LYEL +1.00 across two claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Lyell Immunopharma's share price surged to a new 52-week high of $25.59, up from a previous close of $22.31.
So whatA greater than 14% intraday jump to a new 52-week high signals a significant positive repricing of the stock and a strong shift in investor sentiment.
More positive than 96% of claims this week
Several analysts have issued new reports on Lyell Immunopharma.
So whatAnalyst reports can influence institutional positioning, but the direction and magnitude of their impact cannot be determined without knowing the specific ratings or price targets.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 65% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The stock reached a new 52-week high with a significant increase in share price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
3h ago
−57.6%
Price is moving against the score
$10.71 vs $25.25 close before publication (Dec 5) · not market-adjusted
LYEL chart →
